Trikatu and Haridra drug effectiveness in treatment of abnormal lipids

To evaluate the clinical efficacy of Trikatu and Haridra churna in the management of Medodushti(Dyslipidemia)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/08/044729

Enrollment

Registered

2022-08-17

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E784- Other hyperlipidemia

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients between age group of 25 â?? 60 years in either sex. Diagnosed and confirmed cases of Dyslipidemia (Medodushti) on the basis of criteria given by NCEP ATP III Newly diagnosed case of NIDDM with optimal control Diabetes mellitus

Exclusion criteria

Exclusion criteria: Patients with age below 25 year and above 60 years. Patients have medical history of unstable angina, myocardial infarction, heart failure, stroke within 3 months of study, stage 2hypertension,stage 3 hypertension,type I diabetes mellitus, impaired renal function, hypothyroidism, jaundice, hepatitis, chronic infection and other serious diseases. Pregnancy, lactation and patients having dyslipidemia due to drugs ex. Glucocorticoids, diuretics. BMI >30Kg/m2 Patients not giving consent.

Design outcomes

Primary

Measure	Time frame
Reduction in Cholesterol, Triglycerides, LDL and VLDL and Increases in HDLTimepoint: 2 months	—

Secondary

Measure	Time frame
patient breathlessness, excessive sweating, weakness, Snoring e.t.c symptoms will be reduced.Timepoint: 2 month	—

Countries

India

Contacts

Public ContactRajkumar Yadav

Institute of Medical sciences BHU

anilkumar.singh113@gmail.com8874600002

Outcome results